Q-omics provides the consensus-scored NEK10 profile across patient tissues and cancer cell-line models. NEK10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NEK10 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NEK10 RNA expression shows 18,999 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, THCA, and KIRP as cancer lineages where NEK10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEK10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEK10 survival associations across molecular data types. NEK10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEK10 RNA expression–survival associations across cancer types. High NEK10 expression shows unfavorable associations in ACC, LGG, KICH and STAD, but favorable associations in BRCA and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NEK10 RNA expression.
This table summarizes NEK10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NEK10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEK10 shows lower tumor expression in THCA, KIRC, LUSC, LUAD, BRCA and KICH. The THCA box plot shows higher NEK10 RNA expression in normal versus tumor tissue (log2 FC = −0.404, t-test p < 0.001).
This table shows molecular features associated with NEK10 in patient tissues and cancer cell lines. In patient samples, NEK10 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NEK10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
